A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

This trial tests a three-drug combination — selinexor, azacitidine, and venetoclax (called the SAV regimen) — in older or frail patients with newly diagnosed acute myeloid leukaemia (AML) who are not fit enough to tolerate intensive chemotherapy. All three drugs target different mechanisms that keep leukaemia cells alive. The study aims to find the safest effective dose and assess how well this combination works. **You may be eligible if...** - You are 75 years or older, OR you are 18–74 with significant health conditions (such as heart failure, poor lung function, reduced kidney function, or liver impairment) that make intensive chemotherapy too risky - You have been newly diagnosed with AML (or are fit enough for intensive chemo but prefer not to receive it) - Your liver and kidney function meet minimum thresholds - You are expected to live at least 4 weeks **You may NOT be eligible if...** - You have AML that has spread to the brain or spinal fluid - You have previously received any treatment for AML (except hydroxyurea to lower white cell count) - You have another active cancer - You have known HIV, active hepatitis B, or active hepatitis C Talk to your doctor to see if this trial is right for you.